摘要
目的:探讨重组人血管内皮抑制素(恩度)联合同步放化疗(Concurrent chemoradiotherapy, CCRT)与单独使用CCRT在局部晚期非小细胞肺癌治疗中的疗效评价及毒副作用。方法:收集自2021年5月至2022年5月经病理证实的符合入组标准的局部晚期不可切除非小细胞肺癌患者50例,按照随机双盲法将其分为实验组与对照组,实验组25例患者采用持续泵注恩度联合多西他赛和顺铂同步放化疗治疗,对照组25例患者予以多西他赛和顺铂同步放化疗治疗,观察两组患者的近期疗效及毒副作用。结果:实验组患者的客观缓解率(ORR)高于对照组(92% vs. 80%, P 0.05),治疗结束后实验组较对照组高,P < 0.05,差异有统计学意义。结论:恩度联合CCRT可提高近期疗效,改善患者生存质量,毒副作用无明显增加。
Objective: To investigate the efficacy and toxic side effects of recombinant human vascular endostatin (Endostar) combined with concurrent chemoradiotherapy (CCRT) and CCRT alone in the treatment of locally advanced non-small cell lung cancer. Methods: From May 2021 to May 2022, 50 patients with locally advanced incisive small cell lung cancer who met the admission criteria were collected, and divided into experimental group and control group according to random double- blind method, 25 patients in the experimental group were treated with continuous pump injection grace combined with docetaxel and cisplatin synchronous radiotherapy, and 25 patients in the control group were treated with docetaxel and cisplatin synchronous radiotherapy, and the short- term efficacy and toxic side effects of the two groups were observed. Results: The objective response rate (ORR) of patients in the experimental group was higher than that in the control group (92% vs. 80%, P 0.05), and the experimental group was higher than the control group after treatment, with P < 0.05, and the difference was statistically significant. Conclusion: Endostar unites CCRT can improve the short-term efficacy, improve the quality of life of patients, and there is no significant increase in toxic side effects.
出处
《临床医学进展》
2023年第4期5627-5633,共7页
Advances in Clinical Medicine
